Australian-based Dynamiclear’s product is intended for symptomatic treatment of cold sores and fever blisters in just one application.
A 150 patient-based clinical trial showed that by day three there was a statistically significant greater percentage of patients with erythema, burning, stinging and vesiculation in the topical acyclovir group compared with the Dynamiclear Rapid group.
In addition, 63% of Dynamiclear Rapid users experienced a complete disappearance of cold sore blisters within 72 hours after just one application compared with only 23% of users in the topical acyclovir group.
Paladin also received rights to distribute Dynamiclear’s antiviral formulation for Herpes Simplex Virus-2 infections, which is currently under development, in Canada.
Paladin interim president and CEO Mark Beaudet said Dynamiclear Rapid will complement the company’s growing OTC business, which already includes well known consumer brands like Plan B, Tempra, and Zincofax.
"We believe that Canadian sufferers will prefer Dynamiclear Rapid for the convenience of its single application treatment as well as the speed and efficacy of the relief it delivers," Beaudet added.
The financial details of the agreement have not been disclosed.
Dynamiclear executive director John Spurge said, "This is a major event for Dynamiclear and we have confidence in the market potential of Dynamiclear Rapid in Canada given the continued strong sales in Australia."